The CD4+ Tfh cell, the malignant driver of AITL, highly expresses surface markers, such as CXCR5, PD-1, ICOS and CD40L, that determine its phenotype [7] and can serve as targets for immunotherapy (Figure 4A). This evidence concerns the gene CXCR5 and angioimmunoblastic T-cell lymphoma.